IP Library Patent Application 17412635
Patent Application
App. No. 17/412,635

MEDICAL DEVICES COATED WITH POLYDOPAMINE AND ANTIBODIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/412,635
Abstract

The present disclosure provides for a medical device or a substrate coated with polydopamine which is further linked to ligands such as antibodies and/or antibody fragments. The polydopamine coating and the ligands may be linked through a linker such as an organic polymer.

Claims (20)

1 . A medical device having a coating, wherein the coating comprises (i) polydopamine, (ii) a polyether derivative, and (iii) antibodies and/or antibody fragments, wherein the polydopamine is coated on the medical device and is covalently linked to the polyether derivative, wherein the polyether derivative is covalently linked to the antibodies and/or antibody fragments, wherein the antibodies and/or antibody fragments specifically bind to a cell surface antigen of endothelial progenitor cells or endothelial cells, and wherein the cell surface antigen is CD34.

2 . The medical device of claim 1 , wherein the polyether derivative is polyethylene glycol (PEG), a polyethylene glycol (PEG) derivative, polypropylene glycol (PPG), a polypropylene glycol (PPG) derivative, or combinations thereof.

3 . The medical device of claim 1 , wherein the polyether derivative has an average molecular weight ranging from 200 Daltons to 1,000 Daltons.

4 . The medical device of claim 3 , wherein the polyether derivative has an average molecular weight ranging from 200 Daltons to 350 Daltons.

5 . The medical device of claim 2 , wherein the polyether derivative is PEG.

6 . The medical device of claim 1 , wherein the polyether derivative is covalently linked to an Fc region of the antibodies.

7 . The medical device of claim 1 , wherein the medical device is a stent, an artificial valve, a vascular prosthetic filter, a catheter, a pacemaker, a vascular graft, a synthetic graft, a pacemaker lead, a defibrillator, a patent foramen ovale (PFO) septal closure device, a vascular clip, a vascular aneurysm occluder, a hemodialysis graft, a hemodialysis catheter, an atrioventricular shunt, an aortic aneurysm graft device or components, an artificial venous valve, a shunt, a wire, a sensor, a suture, a vascular anastomosis clip, an indwelling venous or arterial catheter, a vascular sheath or a drug delivery port.

8 . The medical device of claim 1 , wherein the medical device is a stent.

9 . The medical device of claim 1 , wherein the medical device is an artificial heart valve, a vascular stent graft, a synthetic graft, or an artificial venous valve.

10 . The medical device of claim 1 , wherein the medical device is an artificial aortic valve, an artificial pulmonary valve, an artificial mitral valve, or an artificial tricuspid valve.

11 . The medical device of claim 1 , comprising metal, and/or an alloy.

12 . The medical device of claim 1 , further comprising a biocompatible polymer selected from the group consisting of polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polyethylene terephthalate, polyethylene, polyurethane, polypropylene, combinations thereof, and derivatives thereof.

13 . The medical device of claim 1 , wherein the coating further comprises a pharmaceutical substance.

14 . The medical device of claim 13 , wherein the pharmaceutical substance inhibits smooth muscle cell migration and/or proliferation.

15 . The medical device of claim 13 , wherein the pharmaceutical substance is paclitaxel, rapamycin, a rapamycin derivative, sirolimus, everolimus, tacrolimus, biolimus, biolimus A-9, or combinations thereof.

16 . The medical device of claim 1 , wherein the antibodies and/or antibody fragments are humanized antibodies or antibody fragments, or chimeric antibodies or antibody fragments.

17 . The medical device of claim 1 , wherein the antibodies and/or antibody fragments comprise Fab, F(ab′) 2 , or single chain Fv (scFv).

18 . The medical device of claim 1 , wherein the antibodies and/or antibody fragments capture endothelial progenitor cells and/or endothelial cells in vivo when the medical device is implanted into a subject.

19 . A method for treating or preventing a vascular condition in a patient, the method comprising implanting the medical device of claim 1 into the patient.

20 . The method of claim 19 , wherein the vascular condition is atherosclerosis, restenosis, thrombosis, or blood vessel occlusion.

Assignments (2)
CHANGE OF ADDRESS Recorded Jun 15, 2022
From: ORBUSNEICH MEDICAL PTE. LTD.
To: ORBUSNEICH MEDICAL PTE. LTD.
Reel/Frame 060386/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2021
From: KUTRYK, MICHAEL J.B.
To: ORBUSNEICH MEDICAL PTE. LTD.
Reel/Frame 058230/0132 →